시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 세포 및 유전자 치료 CDMO 시장 보고서(2025년)
Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Global Market Report 2025
상품코드 : 1825653
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세포 및 유전자 치료 CDMO 시장 규모는 향후 몇 년 동안 비약적인 성장이 예상됩니다. 2029년에는 CAGR 26.2%로 175억 7,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 치료 용도 확대, 규제 진화, 투자 증가, 기술 혁신, 세계 협력 관계 등에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 개인 맞춤형 치료에 대한 수요 증가, 자동화 및 디지털화 발전, 제조 능력 확대, 새로운 전달 시스템의 등장, 지속가능성 및 환경 영향에 대한 관심 증가 등을 들 수 있습니다.

향후 5년간 26.2%의 성장률 전망은 지난번 전망치보다 0.6% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 무역 마찰은 아일랜드와 덴마크에서 개발된 일회용 바이오리액터와 밀폐형 처리 시스템의 가격을 상승시키고, 제조의 병목현상을 일으켜 첨단 치료법에 대한 환자 접근을 지연시킴으로써 미국의 생명공학 혁신을 저해할 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

암 환자 유병률 증가는 세포-유전자치료제 수탁개발생산(CDMO) 시장의 성장을 견인할 것으로 예측됩니다. 비정상적인 세포의 통제할 수 없는 증식과 확산을 특징으로 하는 암은 인구의 고령화, 생활습관의 변화, 환경 노출, 검출 방법의 개선 등으로 인해 점점 더 흔해지고 있습니다. CDMO는 효능과 환자 결과를 개선하는 혁신적인 표적 치료제를 개발 및 제조함으로써 암 퇴치에 중요한 역할을 하고 있습니다. 예를 들어, 영국에 기반을 둔 자선단체인 맥밀런 암 지원(Macmillan Cancer Support)에 따르면, 영국에서 암을 앓고 있는 사람의 수는 2022년 300만 명에서 2025년 350만 명, 2030년 400만 명, 2030년 530만 명으로 늘어날 것으로 예측했습니다. 그 결과, 암 환자 증가가 세포 및 유전자 치료 CDMO 시장의 성장을 견인하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나재난과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

LSH
영문 목차

영문목차

A cell and gene therapy contract development and manufacturing organization (CDMO) is a specialized company that supports the development, manufacturing, and commercialization of cell-based and gene therapy products. These organizations provide services tailored to the specific needs of companies developing advanced therapies, including biopharmaceutical companies, academic institutions, and government agencies. Cell and gene therapy CDMOs are crucial in speeding up the development and commercialization of advanced therapy products by offering specialized expertise, infrastructure, and services from early-stage development through to commercialization.

The primary product types offered by cell and gene therapy contract development and manufacturing organizations (CDMOs) include gene therapy, gene-modified cell therapy, and cell therapy. Gene therapy involves altering or manipulating the genes within a person's cells to treat or prevent disease. These therapies undergo various phases, including phase 1, phase 2, phase 3, and phase 4, and are developed for a range of indications such as oncology, infectious diseases, neurological disorders, rare diseases, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The cell and gene therapy contract development and manufacturing organization (CDMO) market research report is one of a series of new reports from The Business Research Company that provides cell and gene therapy contract development and manufacturing organization (CDMO) market statistics, including cell and gene therapy contract development and manufacturing organization (CDMO) industry global market size, regional shares, competitors with a cell and gene therapy contract development and manufacturing organization (CDMO) market share, detailed cell and gene therapy contract development and manufacturing organization (CDMO) market segments, market trends, and opportunities, and any further data you may need to thrive in the cell and gene therapy contract development and manufacturing organization (CDMO) industry. This cell and gene therapy contract development and manufacturing organization (CDMO) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell and gene therapy contract development and manufacturing organization (cdmo) market size has grown exponentially in recent years. It will grow from $5.41 billion in 2024 to $6.92 billion in 2025 at a compound annual growth rate (CAGR) of 27.9%. The growth in the historic period can be attributed to increased technological advancements, favorable regulatory frameworks, increased investment, high prevalence of genetic disorders, and an increased number of strategic partnerships.

The cell and gene therapy contract development and manufacturing organization (cdmo) market size is expected to see exponential growth in the next few years. It will grow to $17.57 billion in 2029 at a compound annual growth rate (CAGR) of 26.2%. The growth in the forecast period can be attributed to expanded therapeutic applications, regulatory evolution, increased investment, technological innovations, and global collaboration. Major trends in the forecast period include increased demand for personalized therapies, growth in automation and digitalization, expansion of manufacturing capacities, emergence of novel delivery systems, and heightened focus on sustainability and environmental impact.

The forecast of 26.2% growth over the next five years reflects a modest reduction of 0.6% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. biotech innovation by inflating prices of single-use bioreactors and closed processing systems developed in Ireland and Denmark, resulting in manufacturing bottlenecks that delay patient access to cutting-edge treatments. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of cancer cases is expected to drive the growth of the cell and gene therapy contract development and manufacturing organization (CDMO) market. Cancer, characterized by uncontrolled growth and spread of abnormal cells, is becoming more common due to aging populations, lifestyle changes, environmental exposures, and improved detection methods. CDMOs play a crucial role in combating cancer by developing and manufacturing innovative, targeted treatments that improve efficacy and patient outcomes. For example, according to Macmillan Cancer Support, a UK-based charitable organization, the number of people living with cancer in the UK is projected to rise from 3 million in 2022 to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the increasing prevalence of cancer cases is fueling the growth of the cell and gene therapy CDMO market.

Major companies in the cell and gene therapy contract development and manufacturing organization (CDMO) market are concentrating on broadening their portfolio by integrating advanced solutions such as PluriMatrix technology to improve the scalability, efficiency, and quality of cell-based product manufacturing. PluriMatrix technology is a proprietary system designed for large-scale production of cell-based products. This innovative technology enables 3D expansion of cells on an industrial scale, ensuring high yield and consistent quality through an automated, fully controlled, and validated process. For example, in January 2024, Pluri, a biotech company based in Israel, introduced PluriCDMO, a new business division providing cell therapy manufacturing services as a CDMO. This new division encompasses a 47,000-square-foot good manufacturing practice (GMP) cell therapy production facility. Pluri's newly established division delivers end-to-end services ranging from early preclinical stages to late-stage clinical trials and commercialization, covering process and analytical development, scale-up, validation, logistics, automation, and regulatory-approved comparability studies, as outlined in a company announcement. It harnesses the company's state-of-the-art PluriMatrix technology to provide advanced cell therapy manufacturing services.

In November 2023, Ajinomoto Co. Inc., a Japan-based company specializing in food and biotechnology, purchased Forge Biologics for $620 million. This acquisition enhances Ajinomoto's worldwide expertise in adeno-associated virus (AAV) and plasmid gene therapy manufacturing, strengthening its current contract development and manufacturing services. Forge Biologics, based in the US, is a contract development and manufacturing organization (CDMO) for gene therapy and a clinical-stage therapeutics company.

Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are Pfizer Inc, Merck & Co. Inc., Thermo Fisher Scientific Inc, Novartis AG, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Ajinomoto Co Inc, Lonza Group, Catalent Inc, Charles River Laboratories International Inc, Sartorius Stedim Biotech, Samsung Biologics Co Ltd, WuXi Biologics, Recipharm AB, Almac Group Ltd, KBI Biopharma, Rentschler Biopharma, Bio Elpida, Oxford BioMedica Plc, Avid Bioservices Inc, Cell and Gene Therapy Catapult, VGXI Inc, Genezen Laboratories Inc., Pluri Inc., OmniaBio Inc.

North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The cell and gene therapy contract development and manufacturing organization (CDMO) market includes revenues earned by contract development and manufacturing organizations providing services for the development, manufacturing, and testing of cell and gene therapy products. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cell and gene therapy contract development and manufacturing organization (cdmo) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cell and gene therapy contract development and manufacturing organization (cdmo) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell and gene therapy contract development and manufacturing organization (cdmo) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Characteristics

3. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Trends And Strategies

4. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Growth Analysis And Strategic Analysis Framework

6. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Segmentation

7. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Regional And Country Analysis

8. Asia-Pacific Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

9. China Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

10. India Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

11. Japan Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

12. Australia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

13. Indonesia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

14. South Korea Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

15. Western Europe Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

16. UK Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

17. Germany Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

18. France Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

19. Italy Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

20. Spain Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

21. Eastern Europe Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

22. Russia Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

23. North America Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

24. USA Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

25. Canada Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

26. South America Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

27. Brazil Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

28. Middle East Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

29. Africa Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

30. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Competitive Landscape And Company Profiles

31. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Other Major And Innovative Companies

32. Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

34. Recent Developments In The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market

35. Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기